Richard Malley
Overview
Explore the profile of Richard Malley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Malley R, Lu Y, Sebastian S, Zhang F, Willer D
Expert Rev Vaccines
. 2024 Jan;
23(1):196-204.
PMID: 38174559
Introduction: Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality....
12.
Boerth E, Gong J, Roffler B, Thompson C, Song B, Malley S, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38006003
Bloodstream infections in low- and middle-income countries (LMICs) are most frequently attributed to invasive Salmonella disease caused by four primary serovars of enterica: Typhi, Paratyphi A, Typhimurium, and Enteritidis. We...
13.
Xie J, Kuppermann N, Florin T, Tancredi D, Funk A, Kim K, et al.
Open Forum Infect Dis
. 2023 Oct;
10(10):ofad485.
PMID: 37869403
Background: To assist clinicians with identifying children at risk of severe outcomes, we assessed the association between laboratory findings and severe outcomes among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected...
14.
OHara J, Wakabayashi S, Siddiqi N, Cheung E, Babunovic G, Thompson C, et al.
mBio
. 2023 Feb;
14(1):e0361122.
PMID: 36749098
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide. To date, the mainstay of vaccination involves the use of Mycobacterium bovis bacillus Calmette-Guérin (BCG), a live-attenuated vaccine that...
15.
Zhang F, Boerth E, Gong J, Ma N, Lucas K, Ledue O, et al.
Vaccines (Basel)
. 2023 Jan;
11(1).
PMID: 36679935
Infections by Salmonella Typhi and Paratyphi A strain are still a major cause of morbidity and mortality in developing countries. Generation of antibodies against the Vi capsular polysaccharide of ....
16.
Pichichero M, Malley R, Kaur R, Zagursky R, Anderson P
Expert Rev Vaccines
. 2022 Dec;
22(1):118-138.
PMID: 36565291
Introduction: Despite the introduction of effective pneumococcal conjugate vaccines (PCV), Streptococcus pneumoniae remains a major cause of acute otitis media (AOM) worldwide. New, higher valency vaccines that offer broader serotype...
17.
Cieslewicz B, Makrinos D, Burke H, Bree D, Haridas R, Tonkiss I, et al.
Vaccines (Basel)
. 2022 Jul;
10(7).
PMID: 35891233
Despite the remarkable success of SARS-CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines....
18.
Funk A, Kuppermann N, Florin T, Tancredi D, Xie J, Kim K, et al.
JAMA Netw Open
. 2022 Jul;
5(7):e2223253.
PMID: 35867061
Importance: Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children. Objectives: To estimate the proportion of SARS-CoV-2-positive children with PCCs 90...
19.
Chichili G, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, et al.
Vaccine
. 2022 Jun;
40(31):4190-4198.
PMID: 35690500
Background: Pneumococcal diseases remain prevalent despite available polysaccharide and conjugate vaccines. This phase 1/2 study evaluated safety/tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine (ASP3772) based on high-affinity complexing...
20.
Basset A, Wall E, Mitsi E, Deshusses C, Daly R, Pojar S, et al.
Infect Immun
. 2022 Jun;
90(7):e0017522.
PMID: 35674445
The advent of pneumococcal conjugate vaccines led to the near disappearance of most of the included serotypes in high-income settings but also the rise of nonvaccine-type colonization and disease. Alternative...